Page contentsPage contents Key facts Decision Key facts Active substance padeliporfin di-potassium Therapeutic area Neoplasms benign, malignant and unspecified (incl cysts and polyps) Decision number EMA/PE/0000237903 PIP number EMA/PE/0000237903 Pharmaceutical form(s) Powder for solution for injection Condition(s) / indication(s) Treatment of upper tract urothelial cancer Route(s) of administration Intravenous use Contact for public enquiries Steba Biotech S.A. E-mail: Louis.Clauss@impactbiotech.comTel: +33 687 603 258 Decision type W: decision granting a waiver in all age groups for all conditions or indications Decision date 16/04/2025 Compliance check done No Decision EMA/PE/0000237903 : EMA decision of 16 April 2025 on the granting of a product specific waiver for padeliporfin (dipotassium)Adopted Reference Number: EMADOC-1700519818-2008916 English (EN) (218.74 KB - PDF)First published: 03/07/2026 View Share this page